EstroG-100^® is a patented medicinal plant extract for the treatment of menopausal symptoms

Duck-Joo Lee’s research group publishes its paper regarding the third overall prospective randomised double-blind clinical study on the safety and efficacy of EstroG-100® among 122 women with menopausal symptoms in the USA, showing a significant improvement in the Kupperman menopausal index and individual climacteric symptoms compared to the baseline and also to the placebo group without relevant side effects, such as those that occur after taking oestrogen.

In animal experiments on ovariectomised rats, the research group around Gyuok Lee shows that EstroG-100® can lower the temperature of the tail skin of these rats for one week after a daily injection or prevent the artificial stress-induced rise in tail skin temperature above a certain threshold without this effect being influenced by tamoxifen, thus providing an explanation of why it improves hot flush symptoms in clinical studies.

Ju-Hyun Park’s research group finds – in a pharmacological animal test toxicity study of EstroG-100® administered daily for 26 weeks
up to an administered concentration of 1500 mg/kg except for faecal changes – estrog100.com no toxic effects in male or female Sprague-Dawley rats, neither in the clinical examinations nor in the laboratory parameters or at post-mortem examination, including no changes in individual organs.

The research group around Se Jong Kim finds no oestrogenic activity of the hot water extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas (CPAE) at the human oestrogen receptor in in vitro assays.

Jaeyong Kim’s research group is able to show that the plant extract from Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas promotes anabolic metabolic processes and inhibits degradation processes in the joint in an in vitro experiment set-up using several assays of mouse chondrocyte cells, thus explaining the efficacy of EstroG-100^® on joint pain and osteoporosis from the clinical studies.

Albert Chang publishes the results of his research group’s overall second prospective randomised double-blind placebo-controlled clinical study of the safety and efficacy of EstroG-100® administered daily (or placebo) for twelve weeks to 61 women with climacteric symptoms, reporting significant improvement in the Kupperman menopausal index as well as individual symptoms and vaginal dryness, with no relevant side effects, and this after only six weeks.

The same research group around Seok-Jong Lee determines the mutagenic potential of EstroG-100^® in the bone marrow cells of mice in another, this time in vivo animal test study and, after a dose-finding study and determining the maximum dose of 2000 mg/kg, finds no evidence of damaging effects on the genetic material by EstroG-100^® in the bone marrow cells of male mice, even in the highest applied doses in vitro.

In a somewhat different in vitro experiment set-up, the same working group around Seok-Jong Lee again determines the mutagenic potential in lung cells of Chinese hamsters (Chinese Hamster Lung, CHL/IU) and, after a dose-finding study and determining the maximum dose of 5000 µg/ml, finds no increased rate of chromosomal defects in the examined cells, even in the highest applied doses, and thus no indication of damaging effects on the genome by EstroG-100^®.

Seok-Jong Lee et al. determine the mutagenic potential of EstroG-100® in an in vitro study on strains of Salmonella typhimurium and Escherichia coli. After a dose-finding study and determining the maximum dose of 5000 µg/plate, they find no evidence of harmful effects on the genome by EstroG-100^® on strains of Salmonella typhimurium and Escherichia coli, even at the highest applied doses, and thus no evidence of mutagenic potential.

The research group around Seo-Hee Moon conducts an animal study in male and female Sprague-Dawley rats to approximate the lethal dose of EstroG-100^®. With a single oral administration of various doses, there were no clinical abnormalities or deaths in the test animals studied up to a concentration of 4000 mg/kg, except for altered stools on the first day, so that the lethal dose was assumed to be higher than 4000 mg/kg.

In an in vitro study, the same working group around Jong-Koo Kang shows that there is no binding affinity at the oestrogen receptor alpha or beta and conclude from the results that EstroG-100^® does not exert its effect via the oestrogen pathway.

In a pharma-ocological toxicity study, Jong-Koo Kang’s research group finds no toxic effects in male or female Sprague-Dawley rats, neither in clinical examinations nor in laboratory parameters nor in post-mortem examinations, including no changes in individual organs, when EstroG-100^® is administered daily for 13 weeks up to an administered concentration of 1000 mg/kg, i.e. about 100 times the concentration reached in humans when EstroG-100^® is taken normally.

The research group of Nam-Jin Lee conducts an in vitro study and demonstrates that EstroG-100^® does not activate the proliferation of human oestrogen receptor-positive MCF-7 cells and thus does not seem to have the oestrogen-dependent side effect of traditional hormone therapy in this respect.

The working group around Ki-Ho Lee conducts the first prospective randomised, double-blind, placebo-controlled clinical study on Estromon^® in 48 women over 45 years of age with perimenopausal symptoms who have received the test substance or placebo for 48 weeks and shows that Estromon^®, when taken over one year, significantly improves climacteric symptoms compared with the control group and also estrog100.com compared to the baseline as well as bone density, without any relevant side effects occurring and after only three months.